Desloratadine is Still Effectual and Tolerable for Allergy Sufferers

Desloratadine is Still Effectual and Tolerable for Allergy Sufferers

AntihistamineKnown as the brand name Clarinex, as well as Clarinex D 12 Hour, Desloratadine is a steadfast and tolerable treatment for allergies. Desloratadine offers anti-inflammatory benefits, as it is a selective H(1)-receptor antagonist. Known as a safe and effective antihistamine for both adults and children, it comes as no surprise that IMS Health released positive sales numbers for Clarinex for the 2012 year. Sales of Clarinex RediTabs in specific garnished 5.3 million dollars in sales in the United States for the 2012 year, and projections are encouraging for 2013 as well. Due to the fact that Desloratadine is quickly absorbed and offers a dose-proportional profile, many patients find this allergy treatment to be extremely tolerable. With a half-life of 27 hours, Desloratadine is unaffected by food consumption, and there are no outstanding drug interactions with common medications such as erythromycin and ketonazole. Patients who consume grapefruit juice and grapefruit products regularly can also breathe a sigh of relief while taking Desloratadine, as the metabolism of this antihistamine is also unaffected by the grapefruit family.

Desloratadine is designed to be administered once a day, and the efficacy of this drug is rapidly known. Congestion, nasal symptoms like a runny or stuffy nose and sneezing are all significantly lessened within a short period of time after ingesting Desloratadine. Additionally, patients suffering from asthma have shown sizable reductions of their asthma symptom scores after starting treatments with Desloratadine. As a newer second-generation H1-antihistamine, Desloratadine will not cause drowsiness and a sedated feeling, which many of the older first generation H1-antihistamines caused. It should be noted that Desloratadine disintegrating tablets, also known as Clarinex RediTabs may contain phenylalanine. Inquire with patients as to whether they have phenylketonuria (PKU) before treating them with Desloratadine if it may contain phenylanine. The patent for Clarinex RediTabs expires on July 7, 2019, paving the way for continued research and development of this reliable and formidable allergy treatment.

LGM Pharma is a supplier of Desloratadine CAS# 100643-71-8 for research and development purposes, as well as the sole distributor of the Desloratadine TEVA API for compounding in U.S.. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service